Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

doi:10.1038/s41467-021-26572-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Nature communications - 1 Dec 2021

Gonzalez-Cao Maria, Mayo de Las Casas Clara, Oramas Juana, Berciano-Guerrero Miguel A, de la Cruz Luis, Cerezuela Pablo, Arance Ana, Muñoz-Couselo Eva, Espinosa Enrique, Puertolas Teresa, Diaz Beveridge Roberto, Ochenduszko Sebastian, Villanueva Maria-Jose, Basterretxea Laura, Bellido Lorena, Rodriguez Delvys, Campos Begoña, Montagut Clara, Drozdowskyj Ana, Molina Miguel A, Lopez-Martin Jose Antonio, Berrocal Alfonso

Abstract excerpt

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Pyrimidinones

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 34853302
DOI: 10.1038/s41467-021-26572-6
PMCID: PMC8636498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.PMID 34853302Read ↗

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).Semantic proximity Read ↗

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.Semantic proximity Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Semantic proximity Read ↗

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.Semantic proximity Read ↗

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.Semantic proximity Read ↗

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.